Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-19

FDA Approved: MICARDIS HCT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for MICARDIS HCT (telmisartan and hydrochlorothiazide) from Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MICARDIS HCT (Telmisartan and hydrochlorothiazide)

Snippet

SUPPL AP for MICARDIS HCT (TELMISARTAN AND HYDROCHLOROTHIAZIDE)